Research shows that new compounds based on an anti-nausea medication called ondansetron may help treat type 2 diabetes by blocking an enzyme called PTP1B. According to Gram Research analysis of this 2026 study, two compounds called FN-06 and FN-10 successfully blocked this enzyme in laboratory tests and lowered blood sugar in animal studies while protecting liver function. However, these compounds have not been tested in humans yet and remain in early development stages.
Researchers have developed new compounds based on ondansetron, a common anti-nausea medication, that may help treat type 2 diabetes by targeting a specific enzyme called PTP1B. According to Gram Research analysis, this 2026 study tested these new compounds using computer simulations, laboratory experiments, and animal studies. The results suggest that two compounds, called FN-06 and FN-10, could lower blood sugar levels while also protecting the liver. While these findings are promising, the compounds are still in early development stages and have not yet been tested in humans, so more research is needed before they could become available as diabetes treatments.
Key Statistics
A 2026 research article published in Frontiers in Pharmacology found that the ondansetron derivative compound FN-06 showed the strongest binding to the PTP1B enzyme with a docking score of -7.317 kcal/mol in computer simulations.
Laboratory experiments in the 2026 study demonstrated that ondansetron derivative FN-10 successfully inhibited the PTP1B enzyme directly, confirming that the computer-predicted compounds worked as designed in test-tube conditions.
Animal studies in the 2026 research showed that ondansetron derivatives FN-06 and FN-10 demonstrated both anti-diabetic effects and hepatoprotective (liver-protecting) properties, suggesting potential dual benefits for type 2 diabetes treatment.
The Quick Take
- What they studied: Whether new chemical compounds based on an existing anti-nausea drug could help control blood sugar in type 2 diabetes by blocking an enzyme that contributes to the disease
- Who participated: The study used computer models, test-tube experiments, and laboratory animals (specific sample sizes not provided in the abstract). No human participants were involved in this early-stage research
- Key finding: Two new compounds, FN-06 and FN-10, successfully blocked the PTP1B enzyme in lab tests and showed anti-diabetic effects in animal studies, suggesting they could potentially lower blood sugar levels
- What it means for you: These results are encouraging for future diabetes treatment development, but these compounds are still in very early stages. They have not been tested in humans yet, so it will be several years before we know if they’re safe and effective for people with diabetes
The Research Details
This research used a three-step approach to test new diabetes drug candidates. First, researchers used computer programs to predict how well the new compounds would attach to and block the PTP1B enzyme—the same way scientists use computer models to design video game characters before building them. Second, they performed laboratory experiments in test tubes to confirm that the compounds actually blocked the enzyme as predicted. Third, they tested the compounds in animal studies to see if they could lower blood sugar levels and protect liver function in living organisms.
The compounds were created by chemically modifying ondansetron, a medication already approved for treating nausea. Researchers combined ondansetron with different chemical structures to create new variations that might work better as diabetes treatments. This approach of modifying existing drugs is common in pharmaceutical research because it can be faster and safer than creating entirely new compounds from scratch.
The study focused on PTP1B because this enzyme plays a key role in how the body controls blood sugar. When too much PTP1B is present, it interferes with the body’s ability to respond to insulin, leading to high blood sugar and type 2 diabetes. By blocking this enzyme, the new compounds might help the body use insulin more effectively.
This research matters because current diabetes treatments don’t work well for everyone and can have side effects. Finding new ways to target the root causes of type 2 diabetes could lead to better treatment options. The three-step approach used here—computer prediction, lab testing, and animal studies—is the standard way scientists safely develop new medications before they’re ever tested in humans. This careful process helps ensure that only the most promising compounds move forward to human trials.
This study represents early-stage drug development research. The strengths include using multiple testing methods (computer, lab, and animal studies) to confirm results, and testing in a peer-reviewed journal. However, the limitations are significant: no human participants were involved, specific sample sizes weren’t provided, and the compounds have not been tested for safety or effectiveness in people. Early-stage research like this often doesn’t lead to approved medications, so results should be viewed as preliminary and promising rather than definitive
What the Results Show
The computer analysis showed that compound FN-06 had the strongest ability to bind to and block the PTP1B enzyme, with a docking score of -7.317 kcal/mol (a measurement of how well a drug fits into its target). The computer simulations also indicated that this compound would remain stable in the body, suggesting it could work effectively as a medication.
Laboratory experiments confirmed these computer predictions. When researchers tested the compounds in test tubes, compound FN-10 successfully blocked the PTP1B enzyme directly, demonstrating that the compounds worked as designed. This is an important step because it proves the theory behind the drug design actually works in practice.
Animal studies showed that both FN-06 and FN-10 had anti-diabetic effects, meaning they helped lower blood sugar levels in the test animals. Additionally, the compounds appeared to protect liver function, which is important because diabetes can damage the liver. The parent compound ondansetron (the original anti-nausea medication) also showed some beneficial effects, though the new derivatives appeared more effective.
The research demonstrated that modifying ondansetron to create new compounds could enhance its ability to treat diabetes while maintaining safety. The compounds showed hepatoprotective effects, meaning they helped protect liver cells from damage—an important benefit since type 2 diabetes often leads to liver problems. The fact that multiple compounds showed activity suggests that researchers have identified a promising chemical structure that could be further refined to create even better diabetes treatments.
Previous attempts to develop PTP1B inhibitors have often failed because the compounds either weren’t selective enough (they blocked other enzymes too, causing side effects) or were toxic to the body. This research suggests that using ondansetron as a starting point might overcome these problems. By building on an existing medication that’s already known to be safe in humans, researchers may be able to develop PTP1B inhibitors with fewer side effects than completely new compounds. However, this study is the first to test these specific ondansetron derivatives, so direct comparisons to other approaches are limited.
This study has several important limitations. First, no human participants were involved—only computer models, test tubes, and animals were used. Results in animals don’t always translate to humans. Second, the abstract doesn’t specify how many animals were used or provide detailed statistical analysis of the results. Third, the compounds have not been tested for safety in humans, so we don’t know if they would cause side effects. Fourth, long-term effects are unknown. Finally, this is very early-stage research; many promising compounds fail during later development stages before reaching patients
The Bottom Line
Based on this early research, there are no recommendations for patients yet. These compounds are not available as treatments and should not be used outside of research settings. However, people with type 2 diabetes should continue following their doctor’s advice regarding current approved treatments. For researchers and pharmaceutical companies, these findings suggest that ondansetron derivatives warrant further investigation as potential diabetes treatments, though much more research is needed before human trials could begin. Confidence level: Low to Moderate (this is preliminary research)
People with type 2 diabetes should be aware of this research as a sign that scientists are actively developing new treatment options, which may provide hope for better medications in the future. Researchers and pharmaceutical companies should pay attention as this work identifies a new chemical approach to diabetes treatment. People should NOT try to use ondansetron (the original anti-nausea medication) as a diabetes treatment based on this research, as it was not designed for that purpose and could be unsafe. Healthcare providers should monitor this research area for future developments
If these compounds continue to show promise, the typical timeline for drug development would be: 2-3 years for additional laboratory and animal studies, 1-2 years for regulatory approval to begin human trials, 3-5 years for human clinical trials in phases 1-3, and then 1-2 years for regulatory review. This means it would likely be 7-13 years minimum before these compounds could potentially become available as diabetes treatments, if they successfully complete all development stages
Frequently Asked Questions
Can I use ondansetron for type 2 diabetes based on this research?
No. This research is preliminary and only tested new chemical modifications of ondansetron in animals, not the original medication in humans. Ondansetron is approved only for treating nausea. Using it for diabetes without medical supervision could be unsafe. Consult your doctor about approved diabetes treatments
When will these new diabetes drugs be available?
These compounds are in very early development stages. If they continue progressing successfully through all required testing phases, it would likely take 7-13 years minimum before they could potentially become available as treatments. Many promising compounds don’t make it to market, so availability is uncertain
How does blocking PTP1B help control blood sugar?
PTP1B is an enzyme that interferes with insulin signaling in the body. When PTP1B is overactive, cells can’t respond properly to insulin, causing blood sugar to rise. By blocking this enzyme, the body can use insulin more effectively, helping to lower and control blood sugar levels
Why test these compounds in animals before humans?
Animal studies help researchers understand if compounds are safe and effective before testing them in people. This protects human safety by identifying potential side effects early. Results in animals don’t always match humans, but they provide essential safety information required by regulatory agencies before human trials can begin
What makes these compounds better than current diabetes medications?
Current research suggests these compounds may work through a different mechanism (blocking PTP1B) than many existing diabetes drugs, potentially offering an alternative for people who don’t respond well to current treatments. However, they haven’t been tested in humans yet, so we can’t confirm they’re actually better until human trials are completed
Want to Apply This Research?
- Users with type 2 diabetes can track their current blood sugar readings, medication adherence, and A1C test results in the app to establish a baseline. As new treatments become available in the future, they can compare these metrics to see if new medications improve their diabetes control
- While waiting for new treatments like these to be developed, users can use the app to track and improve lifestyle factors that help control type 2 diabetes: daily steps walked, meals logged with carbohydrate counts, water intake, and sleep hours. These behaviors significantly impact blood sugar control today
- Set up monthly reminders to log blood sugar readings and weight. Create a notification to check for updates on new diabetes treatments. Track trends in blood sugar control over 3-month periods to see if current lifestyle and medication changes are working. Share reports with healthcare providers during regular checkups
This research represents early-stage drug development and has not been tested in humans. The compounds discussed are not approved for any medical use and are not available as treatments. People with type 2 diabetes should continue following their healthcare provider’s treatment recommendations and not attempt to use these experimental compounds or modify their current medications based on this research. This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before making any changes to diabetes treatment or management
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.